Evidence map›Paper›PMID 25710288›Full record

Observational studyAIDS (London, England)2015

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.

Alexander J Szubert, Victor Musiime, Mutsawashe Bwakura-Dangarembizi, Patricia Nahirya-Ntege, Adeodata Kekitiinwa, Diana M Gibb, Kusum Nathoo, Andrew J Prendergast, A Sarah Walker, ARROW Trial Team

Abstract readObservational Study
In one paragraph

Observational study in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Article
  4. Article
  5. Update: Vitamin DTrials · 2024
    Article
  6. Impaired Bone Architecture in Peripubertal Children With HIV, Despite Treatment With Antiretroviral Therapy: A Cross-Sectional Study From Zimbabwe.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
    Article
  7. Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Vitamin DTrials · 2022
    Article
  12. Article
  13. Article
  14. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexander J SzubertaMRC Clinical Trials Unit at University College London, London, UK bJoint Clinical Research Centre cMakerere University College of Health Sciences, Kampala, Uganda dUniversity of Zimbabwe, Harare, Zimbabwe eMedical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe fPaediatric Infectious Diseases Clinic/Baylor - Uganda, Mulago Hospital, Kampala, Uganda gQueen Mary University of London, London, UK. *All the authors contributed equally to the writing of this article.
Victor Musiime
Mutsawashe Bwakura-Dangarembizi
Patricia Nahirya-Ntege
Adeodata Kekitiinwa
Diana M Gibb
Kusum Nathoo
Andrew J Prendergast
A Sarah Walker
ARROW Trial Team

Funding

Medical Research Council MC_EX_G0300400Wellcome Trust 093768/Z/10/ZWellcome Trust 100714
6 · The paper itself

Abstract

objectivesTo estimate age at attaining Tanner stages in Ugandan/Zimbabwean HIV-infected children initiating antiretroviral therapy (ART) in older childhood and investigate predictors of delayed puberty, particularly age at ART initiation.

designObservational analysis within a randomized trial.

methodsTanner staging was assessed every 24 weeks from 10 years of age, menarche every 12 weeks and height every 4-6 weeks. Age at attaining different Tanner stages was estimated using normal interval regression, considering predictors using multivariable regression. Growth was estimated using multilevel models with child-specific intercepts and trajectories.

resultsMedian age at ART initiation was 9.4 years (inter-quartile range 7.8, 11.3) (n = 582). At the first assessment, the majority (80.2%) were in Tanner stage 1; median follow-up with staging was 2.8 years. There was a strong delaying effect of older age at ART initiation on age at attaining all Tanner stages (P < 0.05) and menarche (P = 0.02); in boys the delaying effect generally weakened with older age. There were additional significant delays associated with greater impairments in pre-ART height-for-age Z-score (P < 0.05) in both sexes and pre-ART BMI-for-age in girls (P < 0.05). There was no evidence that pre-ART immuno-suppression independently delayed puberty or menarche. However, older children/adolescents had significant growth spurts in intermediate Tanner stages, and were still significantly increasing their height when in Tanner stage 5 (P < 0.01).

conclusionDelaying ART initiation until older childhood substantially delays pubertal development and menarche, independently of immuno-suppression. This highlights that factors other than CD4, such as pubertal development, need consideration when making decisions about timing of ART initiation in older children.

Indexed as

Adolescent DevelopmentAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveHIV InfectionsAdolescentAnthropometryChildChild, PreschoolFemaleHumansInfantMaleRandomized Controlled Trials as TopicUgandaZimbabweAnti-Retroviral Agents

Identifiers

PMID25710288
PMCPMC4342414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.